Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation

Courtney V. Fletcher, Barbara J. Chinnock, Beverly Chace, Henry H. Balfour

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease were evaluated in 12 patients undergoing renal transplantation. A 12-week course beginning 24 hours before transplantation was administered in doses of 800 to 3200 mg/day based on renal function. Acyclovir plasma concentrations were measured by RIA on posttransplant days 1 or 2 and 5, 6, or 7. Mean peak and trough concentrations on days 5, 6, or 7 were 25 and 18 μmol/L, respectively. The pharmacokinetic model predicted acyclovir concentrations with a precision of 4.1 μmol/L and bias of -1.19 μmol/L. Estimates of individual pharmacokinetic parameters were consistent with literature and a priori values. Two of six adverse events were attributable to acyclovir; both resolved with dose modification. The dosage adjustment scheme and pharmacokinetic model performed well, allowing us to safely administer high-dose oral acyclovir immediately after renal transplantation. We are proceeding with a placebo-controlled study to assess efficacy for suppression of posttransplant cytomegalovirus disease.

Original languageEnglish (US)
Pages (from-to)158-163
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume44
Issue number2
DOIs
StatePublished - Aug 1988

Fingerprint

Acyclovir
Cytomegalovirus
Kidney Transplantation
Pharmacokinetics
Safety
Transplantation
Placebos
Kidney

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation. / Fletcher, Courtney V.; Chinnock, Barbara J.; Chace, Beverly; Balfour, Henry H.

In: Clinical Pharmacology and Therapeutics, Vol. 44, No. 2, 08.1988, p. 158-163.

Research output: Contribution to journalArticle

@article{511c9501e7414e7ab84cb95bc1c222c4,
title = "Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation",
abstract = "The pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease were evaluated in 12 patients undergoing renal transplantation. A 12-week course beginning 24 hours before transplantation was administered in doses of 800 to 3200 mg/day based on renal function. Acyclovir plasma concentrations were measured by RIA on posttransplant days 1 or 2 and 5, 6, or 7. Mean peak and trough concentrations on days 5, 6, or 7 were 25 and 18 μmol/L, respectively. The pharmacokinetic model predicted acyclovir concentrations with a precision of 4.1 μmol/L and bias of -1.19 μmol/L. Estimates of individual pharmacokinetic parameters were consistent with literature and a priori values. Two of six adverse events were attributable to acyclovir; both resolved with dose modification. The dosage adjustment scheme and pharmacokinetic model performed well, allowing us to safely administer high-dose oral acyclovir immediately after renal transplantation. We are proceeding with a placebo-controlled study to assess efficacy for suppression of posttransplant cytomegalovirus disease.",
author = "Fletcher, {Courtney V.} and Chinnock, {Barbara J.} and Beverly Chace and Balfour, {Henry H.}",
year = "1988",
month = "8",
doi = "10.1038/clpt.1988.131",
language = "English (US)",
volume = "44",
pages = "158--163",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation

AU - Fletcher, Courtney V.

AU - Chinnock, Barbara J.

AU - Chace, Beverly

AU - Balfour, Henry H.

PY - 1988/8

Y1 - 1988/8

N2 - The pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease were evaluated in 12 patients undergoing renal transplantation. A 12-week course beginning 24 hours before transplantation was administered in doses of 800 to 3200 mg/day based on renal function. Acyclovir plasma concentrations were measured by RIA on posttransplant days 1 or 2 and 5, 6, or 7. Mean peak and trough concentrations on days 5, 6, or 7 were 25 and 18 μmol/L, respectively. The pharmacokinetic model predicted acyclovir concentrations with a precision of 4.1 μmol/L and bias of -1.19 μmol/L. Estimates of individual pharmacokinetic parameters were consistent with literature and a priori values. Two of six adverse events were attributable to acyclovir; both resolved with dose modification. The dosage adjustment scheme and pharmacokinetic model performed well, allowing us to safely administer high-dose oral acyclovir immediately after renal transplantation. We are proceeding with a placebo-controlled study to assess efficacy for suppression of posttransplant cytomegalovirus disease.

AB - The pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease were evaluated in 12 patients undergoing renal transplantation. A 12-week course beginning 24 hours before transplantation was administered in doses of 800 to 3200 mg/day based on renal function. Acyclovir plasma concentrations were measured by RIA on posttransplant days 1 or 2 and 5, 6, or 7. Mean peak and trough concentrations on days 5, 6, or 7 were 25 and 18 μmol/L, respectively. The pharmacokinetic model predicted acyclovir concentrations with a precision of 4.1 μmol/L and bias of -1.19 μmol/L. Estimates of individual pharmacokinetic parameters were consistent with literature and a priori values. Two of six adverse events were attributable to acyclovir; both resolved with dose modification. The dosage adjustment scheme and pharmacokinetic model performed well, allowing us to safely administer high-dose oral acyclovir immediately after renal transplantation. We are proceeding with a placebo-controlled study to assess efficacy for suppression of posttransplant cytomegalovirus disease.

UR - http://www.scopus.com/inward/record.url?scp=0023730633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023730633&partnerID=8YFLogxK

U2 - 10.1038/clpt.1988.131

DO - 10.1038/clpt.1988.131

M3 - Article

C2 - 2840229

AN - SCOPUS:0023730633

VL - 44

SP - 158

EP - 163

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -